---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-035135"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:59:32.305046+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20

## Summary
- GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
- Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.
- Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.
- Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.
- Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY.

## SEC filing metadata
- accession: 0001628280-25-035135
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/0001628280-25-035135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/abt-20250717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-035135
- JSON: https://secwatch.observer/filing/0001628280-25-035135.json
- Plain text: https://secwatch.observer/filing/0001628280-25-035135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.